cyrilzakka/clinical-trials huggingface dataset:
Arthroscopic Treatment Combined With PRP Injection for Refractory Elbow Epicondylitis

This study is a prospective randomized controlled study of different arthroscopic treatments for refractory external humeral epicondylitis combined with platelet rich plasma (PRP) injection. The patients with intractable external humeral epicondylitis were randomly divided into groups before the operation. After the arthroscopic operation was completed, they were divided into a local PRP injection group and a control group (normal saline) to perform additional operations on the damaged tendons, each for up to half a year after the operation. In different time periods, the quantitative and qualitative indicators including pain, functional score, muscle strength, MRI performance, etc. were compared between groups at the same time period to evaluate the difference in the effect of arthroscopic treatment combined with PRP on the treatment of damaged tendons. Determine the effectiveness of PRP. At the same time, in the process of arthroscopic treatment, look for risk factors that affect the curative effect of intractable external humeral epicondylitis, as well as the causes and prevention of common complications.


Eligibility Criteria:
Inclusion Criteria:

* Clinically diagnosed patients with refractory external humeral epicondylitis (preoperative MRI confirmed loss of ECRB integrity) patients who have received non-surgical treatment with poor efficacy
* Young and middle-aged patients aged 20 to 60, who have not previously received local injection therapy
* Voluntarily accept randomized controlled grouping, cooperate with treatment and follow up patients
* No other comorbidities or medical diseases affect the surgical patients
* Unilateral disease

Exclusion Criteria:

* Early patients who have not received standard non-surgical treatment
* Patients who have received hormone injections or "small needle knife therapy" and other invasive procedures within three months before surgery, poor skin conditions, and local infections
* Elderly people older than 60 years old and patients younger than 20 years old
* Unable to accept randomization, insufficient follow-up time or lost to follow-up
* Bilateral disease
* Combined immune disease
Fluorescent Thoracoscopy Used in Surgery for Palmar Hyperhidrosis

T3/T4 endoscopic thoracic sympathicotomy is a widely accepted and effective treatment for primary palmar hyperhidrosis. However, sympathetic ganglions are invisible with traditional thoracoscopy and until now, the location of ganglions are confirmed by rib indirectly. The team from thoracic department of Peking University People's Hospital discovered that the sympathetic ganglions can be visualized with fluorescent thoracoscopy. Thus, investigators want to apply fluorescent thoracoscopy in sympathicotomy of palmar hyperhidrosis, to conduct a more precise operation and compare the efficiency of the novel and traditional methods.


Eligibility Criteria:
Inclusion Criteria:

1. Diagnosed with primary palmar hyperhydrosis.
2. Accept surgical treatment and signed informed consent.

Exclusion Criteria:

1. Liver dysfunction.
2. Allergic to indocyanine green.
3. Can't tolerate thoracoscopic surgery.
Fibrinolysis Before Cardiopulmonary Bypass?

It is common practice to use antifibrinolytic agents before and during cardiopulmonary bypass. They are not without side effects. The investigators want to show that there is no proof of fibrinolysis in standard sternotomy cardiac surgery patients before cardiopulmonary bypass, and that antifibrinolytic agents should only be started on cardiopulmonary bypass.

Double-blind, placebo controlled, prospective study in two groups of 20 patients. Control group (A) receives standard Epsilonaminocaproic acid treatment before cardiopulmonary bypass (10 gr loading dose, and 1 gr/hr infusion), and second group (B) receives placebo. Before start of Epsilonaminocaproic acid/placebo, D-Dimers and Thromboelastography are measured, repeated just before full heparinization. After heparinization group A receives placebo, and group B Epsilonaminocaproic acid.

Eligibility Criteria:
Inclusion Criteria:

* All adult patients, undergoing first time sternotomy for Coronary artery bypass grafting/Aortic valve replacement/aortic surgery

Exclusion Criteria:

* Resternotomy, renal insufficiency, deep hypothermia, age \< 18 yrs
Transversus Thoracic Muscle Plane Block for Open Heart Surgery

Poststernotomy pain is a complication of cardiac surgery. Poorly controlled pain is associated with myocardial ischemia, cardiac arrhythmias, hypercoagulability, pulmonary complications, and increased rates of delirium and wound infection.

The transverse thoracic muscle plane (TTMP) block is a novel plane block that provide pain for sternotomy. The aim of this study was to evaluate the analgesic effect of ultrasound guided TTMP block in patients undergoing open heart surgery.


Eligibility Criteria:
Inclusion Criteria:

American Society of Anesthesiologist's physiologic state I-III patients Undergoing Open Heart Surgery

Exclusion Criteria:

chronic pain bleeding disorders renal or hepatic insufficiency patients on chronic non-steroidal anti-inflammatory medications emergency cases
INCA: Intracranial Aneurysm Treatment With NeXsys

Prospective, single center first-in-man study of use of device for intracranial aneurysm occlusion

Prospective, single center first-in-man study of use of device for intracranial aneurysm occlusion. Target aneurysms are small unruptured aneurysms in the anterior and posterior circulation.

Eligibility Criteria:
Inclusion Criteria:

* Age 18-80 years at screening
* Unruptured saccular IA in the anterior or posterior circulation with dimensions consistent with Table 2
* IA appears suitable for NeXsys device
* Patient willing to comply with study requirements
* Patient able to understand and sign a study-specific informed consent form

Exclusion Criteria:

* Ruptured IA
* Any other IA that requires treatment in the next year
* IA width \>10 mm
* IA neck \>9 mm
* IA has important flow from its base such that occluding the IA would cause stroke
* Target IA contains any device (e.g., coils)
* Inability to access the target IA with microcatheter
* Any congenital or iatrogenic coagulopathy
* Platelet count \<50,000/microliter
* Known allergy to platinum, nickel or titanium
* Known allergy to contrast agents
* Stenosis of the target IA's parent vessel \>50%
* Taking daily aspirin or other platelet inhibitor (clopidogrel or equivalent)
* Taking any anticoagulants (e.g., warfarin)
* Pregnant or planning pregnancy in the next 2 years
* Other medical conditions that could increase the risk of neurovascular procedures (e.g., liver failure, cancer, etc.)
* Participating in another study with investigational devices or drugs
The Effect of Conservative Treatment on Perceptual and Cognitive Asymmetry in Scoliosis

Adolescent idiopathic scoliosis (AIS) patients have been found to exhibit cortical asymmetry. This study aimed to examine the impact of conservative treatments on perceptual and cognitive asymmetry in the auditory system assessed by dichotic listening in AIS patients with thoracic major curves.

Background: Adolescent idiopathic scoliosis (AIS) patients have been found to exhibit cortical asymmetry. This study aimed to examine the impact of conservative treatments on perceptual and cognitive asymmetry in the auditory system assessed by dichotic listening in AIS patients with thoracic major curves. Method: This study involved 30 AIS patients and 21 healthy subjects. The intervention group used a Cheneau brace and performed 18 Schroth Best Practice (SBP) exercise sessions. Auditory lateralization was assessed using the Dichotic Listening Paradigm (DLP) in both groups before and after the intervention.

Eligibility Criteria:
Inclusion Criteria for Intervention Group:

* Having been diagnosed with AIS,
* Being 10-16 years of age,
* Having a Cobb angle of between 20° and 50°
* Risser's sign of 0-3,
* Having right thoracic scoliosis,
* Being right-handed,
* Having received no previous treatment that may affect scoliosis,
* Having no chronic disease requiring the use of medication.

Inclusion Criteria for Intervention Group:

* Participants aged 10-16 years

Exclusion Criteria for both groups:

* Having previous spinal operations,
* Hearing loss, or the presence of other muscular, neurological, or rheumatic diseases.
Freder1k-Study - Testing Infants for Type 1 Diabetes Risk

The Freder1k-Study will identify infants who have a high genetic risk of type 1 diabetes.

Type 1 diabetes is a common chronic disease in childhood and is increasing in incidence. Type 1 diabetes is diagnosed by hyperglycemia often in combination with symptoms of weight loss, thirst, fatigue and frequent urination, sometimes with ketoacidosis. The clinical onset is preceded by an asymptomatic phase identified by serum multiple beta-cell autoantibodies. Neonates and infants who are at increased risk to develop multiple beta-cell autoantibodies and type 1 diabetes can now be identified using genetic markers. This provides opportunity for introducing early therapies to prevent beta-cell autoimmunity and type 1 diabetes.

Eligibility Criteria:
Inclusion Criteria:

* Age: up to age 6 weeks
* provided written informed consent by custodial parent

Exclusion Criteria:

-
Clinical Trial on the Effectiveness of Citrolive

The clinical trial consists in checking the antioxidant effect of citrolive on low density cholesterol.

The clinical trial consists in checking the antioxidant effect of citrolive on low density cholesterol. To do this, volunteers consume the product under study or placebo for three months.

Tests will be performed before and after ingestion of the product.

Eligibility Criteria:
Inclusion Criteria:

1. Not belonging to the group of individuals considered as priorities by the Third Joint Task Force for the prevention of cardiovascular diseases due to high risk.
2. Present total cholesterol figures greater than 200 milligrams / deciliter and / or low density cholesterol figures greater than 130 milligrams / deciliter so that after applying the cardiovascular risk table (SCORE) they present a current risk of less than 5% of suffer an ischemic event in a period of 10 years, being without pharmacological treatment.
3. Present several cardiovascular risk factors with cholesterolemia figures close to 200 milligrams / deciliters and / or low density cholesterol figures close to 130 milligrams / deciliters.

Exclusion Criteria:

1. chronic or terminal illness.
Pediatric Elective Intubation With and Without Muscle Relaxation Utilizing the Shikani Optical Stylet

The investigators' primary specific aims are to demonstrate that:

1. Pediatric patients with normal airways, undergoing elective surgical procedures, can be successfully intubated when deeply sedated, without the use of muscle relaxants using the Shikani Optical Stylet.
2. Shikani intubation of pediatric patients is equally effective in children that are deeply sedated or paralyzed as evidenced by a non-significant difference in:

   * Time to intubation (defined as no more than a 30 second time difference between the two groups);
   * Incidence of adverse events.


Eligibility Criteria:
Inclusion Criteria:

* 6 months of age to 17 years of age (not yet 18)
* Male or female
* English or Spanish speaking
* Normal airway (Mallampati Classification )
* American Society of Anesthesiology Physical Status Classification I or II
* Elective surgical procedure expected to last at least 45 minutes in length
* Written informed consent/assent for participation given by the parent legal guardian and subject (if applicable)

Exclusion Criteria:

* \< 6 months of age, \> 17 years of age
* Difficult airway (Mallampati Classification)
* History of previous difficult intubation, suspected abnormal airway: \*micrognathia

  * facial trauma
  * airway tumor
  * epiglottitis
  * retropharyngeal abscess
  * foreign body, etc.
  * Scheduled for non-elective, emergent OR procedure
  * Parent, legal guardian, or subject is unavailable or unwilling to consent for study participation
Screening of Endovascular Thrombectomy With MRI in Acute Ischemic Stroke

The goal of this observational study is to learn about the role of MRI evaluation based on FVH-DWI mismatch principle in preoperative evaluation of endovascular thrombolectomy.

The main questions it aims to answer are:

* The consistency between MRI and perfusion examination in determining EVT indications.
* The consistency of functional independence rate between patients screening with MRI and perfusion.

MRI is the preferred imaging mode in many centers,for the diffusion-weighted imaging (DWI) sequences are highly sensitive to acute cerebral ischemia.In addition, MRI does not require intravenous contrast agent, which is simpler and more popular than perfusion.Fluid-attenuated inversion recovery (FLAIR)sequence vascular hyperintensity(FVH) is defined as focal, serpentine, or linear hyperintensity that usually occurs in the Sylvian fissure and is associated with large-vessel occlusion or stenosis.The FVH-DWI mismatch(defined as the FVH extended beyond the boundary of the DWI cortical lesions) had been confirmed has excellent sensitivity and specificity in predicting PWI-DWI mismatch.It is not well established whether MRI based on FVH-DWI mismatch and perfusion evaluation differ in determining EVT indications and outcomes.

The main objectives of this study were to (1) determine the proportion of patients eligible for EVT surgery selected by MRI based on FVH-DWI mismatch vs perfusion in a large multicenter registry and (2) identify statistical differences in functional outcomes and safety outcomes between the two evaluation methods.

Patients with ischemic stroke with anterior-circulation large-vessel occlusion in the late (6-24 h) time window from real-world, single center retrospective cohort registry were compared.In the MRI group, patients with FVH-DWI mismatch underwent EVT surgery or were otherwise treated with medication.In the perfusion group, surgical indications referring the DEFUSE 3 standards. The primary outcome was 90-day functional independence rate (mRS score ≤2) in all patients included(including EVT patient and medication patients).Safety outcomes included symptomatic intracranial hemorrhage (sICH), and 90-day mortality.

Eligibility Criteria:
Inclusion Criteria:

* (1) age ≥ 18 years old;
* (2) symptoms consistent with acute ischemic stroke and an onset time of 6-24h;
* (3) CT ASPECTS score≥6 points;NIHSS≥6points; modified Rankin scale (mRS) of 0-2 points prior to stroke;
* (4) internal carotid artery (ICA) and/or M1 segment of middle cerebral artery (MCA-M1) and M2 proximal segment occlusion with definite diagnosis.
* (5)agree to comply with the protocol follow-up requirements.

Exclusion Criteria:

* (1)Image unanalyzable.
* (2)3 months follow-up was not completed
Cognitive Assessment Tools for Huntington's Disease.

The purpose of the current proposal is to expand understanding of two currently available cognitive tools that are not typically used in Huntington Disease (HD) clinical trials that might be useful both for initial screening and for clinical trial application. One is the Coding Test and the other is the Self-Administered Gerocognitive Examination (SAGE). Both the Coding Test and the SAGE have been used for assessments of individuals with other neurodegenerative diseases, including Alzheimer's Disease, Parkinson's Disease and Lewy Body Disease, but data is lacking on their use in individuals with HD.

Subjects will be recruited from the OSU Wexner Medical Center Huntington Society of America Center of Excellence Clinic. Subjects will be scheduled for a one-time visit to complete the study. The entire visit will take approximately 1-1.5 hours. Vital signs (weight, blood pressure, temperature, respiratory rate and pulse) will be conducted. The subject's medical records will be reviewed to obtain their demographics, current medications, medical/surgical/ HD family history, and HD diagnosis details. If any adverse events occur during the research visit they will be documented. Participants will complete cognitive, functional and motor assessments.

Eligibility Criteria:
Inclusion Criteria:

1. Males and females aged 30-65 (inclusive) at the time of signing the informed consent form.
2. Genetic diagnosis of HD as defined by a CAG repeat size ≥ 40.
3. A clinical diagnosis of HD as defined by a Diagnostic Confidence Level (DCL) of 4.
4. Vision and hearing sufficient for compliance with tests.
5. On a stable dose of medications for 30 days prior to the time of signing the informed consent form.

Exclusion Criteria:

1. Age of symptom onset less than 19 years old or greater than 60 years old.
2. Any serious neurological disorder aside from HD, including but not limited to Alzheimer's disease, Parkinson's disease, Frontotemporal dementia, Lewy body dementia, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury... etc. that in the opinion of the investigator is clinically significant.
3. Any ongoing serious medical condition that in the opinion of the investigator is clinically significant. This includes autoimmune diseases, ongoing treatment for cancer, congestive heart failure, severe pulmonary disease, or any history of a seizure disorder (including the need to take anti-epileptics to prevent seizure).
4. Subjects who are pregnant or breast feeding
5. Subjects with a history of a learning disability.
6. Subjects who are unable to provide consent.
S9313B Study of Tumor Tissue Samples From Women With Early-Stage Breast Cancer Enrolled on Clinical Trial SWOG-9313

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients enrolled on clinical trial SWOG-9313 will respond to doxorubicin and cyclophosphamide.

PURPOSE: This laboratory study is looking at tumor tissue samples from women with early-stage breast cancer enrolled on clinical trial SWOG-9313.

OBJECTIVES:

Primary

* To determine if ALDH1 positivity, as determined by IHC staining, identifies a poor prognostic subgroup of women with early-stage breast cancer who have been uniformly treated with adjuvant doxorubicin and cyclophosphamide on clinical trial SWOG-9313.

Secondary

* To determine associations of ALDH1 expression with other known factors that have been determined on clinical trial SWOG-9313, such as estrogen receptor (ER) status, HER2 status, TOPOII, cyclin E, and p27.
* To determine if ALDH1 positivity, as determined by IHC staining, identifies a poor prognostic subgroup within ER and HER2 subgroups in patients treated on clinical trial SWOG-9313.

OUTLINE: This is a multicenter study.

Tumor tissue samples from clinical trial SWOG-9313 are analyzed for ALDH1 expression by IHC.

Eligibility Criteria:
DISEASE CHARACTERISTICS:

* Tumor samples collected from women diagnosed with early-stage breast cancer on clinical trial SWOG-9313 available

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
Comparative Effects of Hang Clean and Half Squat Training Program Among Basketball Players

The goal of this randomized controlled trial is to compare the effects of hang clean and half squat training programs on vertical jump performance and strength in male basketball players aged 18-35 years. The main questions it aims to answer are: Does a hang clean training program improve vertical jump performance in basketball players? Does a half squat training program improve vertical jump performance in basketball players? Researchers will compare the hang clean training group to the half squat training group to see if there is a significant difference in the improvement of vertical jump performance and strength. Participants who meet the inclusion criteria will be enrolled and allocated in group A \& B through sealed envelop method by Non-probability Convenient random sampling technique. Subjects in Group A will receive hang clean training. Group B will receive half squat training, attend pre- and post-testing assessments of vertical jump performance and strength

Explosive strength is a crucial factor in basketball performance, and various training programs have been developed to improve it. The goal of this randomized controlled trial is to determine the effectiveness of a 12-weeks hang clean training program versus a 12-week half squat training program in improving vertical jump performance and strength in male basketball players aged 18-35 years. The main questions it aims to answer are: Is hang clean training effective in improving vertical jump performance and strength in basketball players? Is half squat training effective in improving vertical jump performance and strength in basketball players? Researchers will compare the hang clean training group to the half squat training group to see if there is a significant difference in the improvement of vertical jump performance and strength. Ethical approval is taken from ethical committee of Riphah International University, Lahore. Participants who meet the inclusion criteria will be enrolled and allocated in group A \& B through sealed envelop method by Non-probability Convenient random sampling technique. Study will be carried in basketball courts at Lahore. Participants will be randomly assigned to either the HCL or HSQ training group. Group A will receive hang clean training. Group B will receive half squat training.

Eligibility Criteria:
Inclusion Criteria:

* Male Basketball player
* Having experience with Weight-lifting movements, Squats, and Deadlifts
* No history of anterior cruciate ligament injuries
* No present complaint of Injury.
* 3 years of Professional experience
* Current competitive level

Exclusion Criteria:

* Medical condition
* Previous history of LBP
* Orthopedic or health related conditions
* Female
* Inadequate Training Experience
* Exclude Performance-Enhancing Substance
Application and Effect Evaluation of Integrated Nursing and Medical Management in Pediatric Lobar Pneumonia

Integrated nursing and medical management significantly improves clinical symptoms and pulmonary function in children with lobar pneumonia, shortens hospitalization duration, reduces complication rates, and enhances caregiver satisfaction. These findings support its broad clinical applicability and value.

This study aims to evaluate the clinical efficacy of integrated nursing and medical management in the treatment of pediatric lobar pneumonia. Specifically, it assesses its impact on symptom relief, pulmonary function recovery, inflammatory response control, duration of hospitalization, and caregiver satisfaction. Fifty pediatric patients diagnosed with lobar pneumonia and admitted to our hospital between January and December 2023 were selected and randomly assigned to either the observation group or the control group (n = 25 each) using a random number table. The control group received routine nursing care, while the observation group was additionally managed with an integrated nursing and medical approach. The two groups were compared in terms of duration of fever, cough, pulmonary rales, antibiotic treatment, length of hospital stay, pulmonary function parameters (FEV₁, FVC, FEV₁/FVC), inflammatory markers (CRP, WBC, PCT, LDH), overall treatment efficacy, caregiver satisfaction, and incidence of adverse events.

Eligibility Criteria:
Inclusion Criteria:

* (1) Met the diagnostic criteria for lobar pneumonia, presenting with symptoms such as fever, cough, and pulmonary rales, and confirmed by laboratory tests and chest X-ray;
* (2) Aged between 1 and 12 years;
* (3) Informed consent was obtained from the child's legal guardians.

Exclusion Criteria:

* (1)Presence of other concurrent respiratory diseases;
* (2) Congenital or acquired airway malformations, or airway foreign bodies;
* (3) Impaired hepatic or renal function;
* (4) Presence of other systemic diseases;
* (5) Cognitive impairment.